Zobrazeno 1 - 10
of 183
pro vyhledávání: '"Nuriye, Ozdemir"'
Autor:
Orhun Akdogan, Betul Ogut, Osman Sutcuoglu, Aysenur Sert, Fatih Gurler, Nalan Akyurek, Nuriye Ozdemir, Ahmet Ozet, Ozan Yazici
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background Growth differentiation factor-15 (GDF-15), a member of the TGF-β superfamily, is overexpressed in various cancers and facilitates immune evasion by inhibiting T-cell activation. GDFATHER-TRIAL’s phase 2a results demonstrated pr
Externí odkaz:
https://doaj.org/article/db4a573e19b24f1c82b55dbc73a1b3e1
Publikováno v:
Infectious Diseases and Clinical Microbiology. 4:274-279
Objective: Percutaneous transhepatic cholangiography (PTC) is an invasive procedure used in patients with obstructive jaundice in the progress of some malignancies, and its most common complication is infection. We aimed to evaluate the patients who
Publikováno v:
Future Oncology
Introduction: The objective of this study was to evaluate the clinical and laboratory outcomes of solid cancer patients who were reinfected with COVID-19. Methods: Patients who were tested negative on the Coronavirus disease 2019 (COVID-19) PCR test
Autor:
Nuriye Ozdemir, Irem Bilgetekin, Esra Zeynelgil, Mustafa Altinbaş, Ismail Erturk, Selin Akturk Esen, Dogan Uncu, Musa Baris Aykan, Goksen Inanc Imamoglu, Yeşim Yıldız, Cengiz Karacin, Ahmet Ozet, Burak Civelek, Ismail Celik, Gokhan Ucar, Fatma Buğdaycı Başal, Nuri Karadurmus, Ozan Yazıcı, Bedia Dinc, Ibrahim Karadag, Omur Berna Oksuzoglu, Osman Sütcüoğlu, Yakup Ergun, Mutlu Dogan, Tulay Eren
Publikováno v:
Future Oncology
Aim: To evaluate the immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy. Methods: This multicenter, prospective, observational study was conducted with 47 patients receiving active systemic th
Publikováno v:
The Saudi Journal of Gastroenterology, Vol 21, Iss 5, Pp 320-324 (2015)
Background/Aims: The association between platelet–lymphocyte ratio (PLR), neutrophil–lymphocyte ratio (NLR), and survival with response rates were evaluated in metastatic gastric cancer (MGC). Patients and Methods: MGC patients on firstline modif
Externí odkaz:
https://doaj.org/article/e62c7b9d84874cfd9dd2450d7a94ce68
Autor:
Nuriye Ozdemir, Ozan Yazıcı, Oktay Ünsal, Aytug Uner, Osman Sütcüoğlu, Bediz Kurt Inci, Nazan Günel, Demet Döndü Kasım, Gözde Tahtaci, Ahmet Ozet, Volkan Aslan, Fatih Gürler
Publikováno v:
Journal of Oncology Pharmacy Practice. 28:1516-1523
Introduction To evaluate biosimilar understanding and preference trends of medical oncologists in Turkey. Methods A survey consisting of 24 multiple-choice questions with checkbox answers was conducted among medical oncologists. The questionnaire was
Publikováno v:
Euroasian Journal of Hepato-Gastroenterology
Aim Gastric cancer is one of the most common cancers worldwide. In Turkey, stomach cancer is ranked 5th among men and 8th among women in all cancers and is located in the forefront in cancer-related deaths. Signet ring cell adenocarcinoma, which is t
Autor:
Aysegul Ilhan, Bediz Kurt Inci, Fatih Yildiz, Berna Oksuzoglu, Ahmet Özet, Fatih Gürler, Deniz Can Guven, Zafer Arik, Osman Sütcüoğlu, Ozan Yazici, Nuriye Ozdemir, Okan Turhan, Suayib Yalcin
We aimed to compare the efficacy and the safety of the FOLFOX and the FLOT regimens in metastatic gastric cancer (mGC) as first-line treatment. It was a retrospective multicenter observational study. The comparisons between groups were conducted in t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::207f348d2182275a64c910e6e6c6df86
https://avesis.gazi.edu.tr/publication/details/01f81c4e-eb01-4973-95f3-529bd05495a7/oai
https://avesis.gazi.edu.tr/publication/details/01f81c4e-eb01-4973-95f3-529bd05495a7/oai
Autor:
Dogan Uncu, Gokhan Ucar, Deniz Can Guven, Deniz Tural, Nazan Günel, Ozan Yazıcı, Nuriye Ozdemir, Aytug Uner, Osman Sütcüoğlu, Omur Berna Oksuzoglu, Seher Yildiz Tacar, Saadettin Kilickap, Aysegul Ilhan, Ahmet Ozet, Fatih Yildiz, Emrah Eraslan, Nuri Karadurmus
Publikováno v:
Immunotherapy. 13(17)
Background: The aim of this study was to determine the cause of death in patients who died within 30 days after the first dose of immunotherapy. Methods: The data of 1432 patients treated with immunotherapy in six tertiary referral hospitals were ret